Sector: MedicalInterMune, Inc. (NASDAQ: ITMN)
Headlines
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Nov 05, 2009 04:01 PM | ITMN
- InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
Nov 05, 2009 08:02 AM | ITMN
- InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
Nov 04, 2009 08:51 AM | ITMN
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
Nov 03, 2009 08:16 AM | ITMN, VRUS
- InterMune to Present at Oppenheimer Conference
Oct 29, 2009 04:01 PM | ITMN
- InterMune to Release Third Quarter Financial Results on November 5
Oct 29, 2009 07:01 AM | ITMN
- InterMune to Present at JMP Securities Conference
Oct 01, 2009 07:01 AM | ITMN
- InterMune Announces Initiation of Ritonavir-Boosted ITMN-191/RG7227 Study in HCV Patients
Sep 29, 2009 07:11 AM | ITMN
- InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
Sep 17, 2009 07:01 AM | ITMN
- Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
Sep 14, 2009 09:45 AM | ITMN
- Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Aug 19, 2009 04:11 PM | ITMN, RHHBY
- InterMune to Present at Canaccord Adams Conference
Aug 07, 2009 07:00 AM | ITMN
- InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Aug 06, 2009 04:00 PM | ITMN
- BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Aug 06, 2009 06:53 AM | ARNA, AVII, AZN, BMR, CEPH, EPCT
- InterMune to Release Second Quarter Financial Results on August 6
Jul 29, 2009 04:01 PM | ITMN
- InterMune to Present at Goldman Sachs Healthcare Conference
Jun 03, 2009 04:00 PM | ITMN
- Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
May 19, 2009 06:48 PM | ITMN
- Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
May 17, 2009 11:15 AM | ITMN
- Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
May 14, 2009 08:26 AM | ITMN
- InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Apr 30, 2009 04:01 PM | ITMN
- Form 4 HEALY JAMES For: May 21 (10K)
Jun 24, 2009 10:05 PM
- Form 4 KABAKOFF DAVID S For: May 21 (10K)
Jun 24, 2009 09:41 PM
- Form 4 INTERMUNE INC For: May 21 Filed by: LEFF JONATHAN S (10K)
Jun 24, 2009 09:37 PM
- Form 4 Ekman Lars For: May 21 (10K)
Jun 24, 2009 09:36 PM
- Form 4 Seiwert Scott For: May 29 (10K)
Jun 02, 2009 04:05 PM
- Form 4 Seiwert Scott For: May 15 (10K)
May 18, 2009 08:22 PM
- Form 4 ARMSTRONG MARIANNE For: May 13 (10K)
May 15, 2009 11:22 PM
- Form 4 Steele Robin Joan For: May 13 (10K)
May 15, 2009 11:21 PM
- Form 4 Porter Steven Bryant For: May 13 (10K)
May 15, 2009 11:20 PM
- Form 4 Simon Howard Allan For: May 13 (10K)
May 15, 2009 11:19 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ITMN
|
Compare to S&P
|
| YTD |
14.18 %
|
-0.47 %
|
| 4 Weeks |
-17.71 %
|
-18.58 %
|
| 12 Weeks |
-16.69 %
|
-18.76 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 11.76 %
|
|
EPS Growth in Last Year: 11.76 %
|
|
Sales Growth in Last Quarter: 15.74 %
|
|
Sales Growth in Last Quarter: -2.29 %
|
|
